Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 3 to 16

Midazolam‑Ketamine versus Dexmedetomidine to prevent emergence delirium after deep sedation in children with burns

Official title: The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients

Run by Ain Shams University · NCT07519863 · Data updated 2026-11-12

We will try whether a midazolam‑ketamine combination or dexmedetomidine better prevents emergence delirium in children aged 3–16 undergoing deep sedation for burn dressing changes or minor procedures.

More Emergence Delirium in Pediatric Anesthesia trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages3 Years to 16 Years
SexAll
Enrollment60 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedNovember 20, 2025
Main results expectedNovember 2026
Study endsDecember 2026
Registry record updatedApril 9, 2026
Trial IDNCT07519863 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 3–16 years with ASA physical status I–II who are scheduled for elective burn dressing changes or minor interventions and have no significant hepatic, renal, immunological, hematological, or neurological disorders are ideal candidates.

Probably not a fit

Patients with hepatic or renal dysfunction, immunological/hematological disorders, epilepsy, developmental delay or neurological deficits, preoperative hemodynamic instability, need for high‑dose inotropes/vasopressors, or known allergy to the study drugs are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, randomized, controlled Phase 2 study that assigns eligible pediatric burn patients to either an intravenous midazolam‑ketamine combination or intravenous dexmedetomidine for standardized deep sedation. Sedation depth will be kept comparable between groups using a validated sedation scale and standard intraoperative monitoring. Emergence delirium will be measured after the procedure using the Pediatric Anesthesia Emergence Delirium (PAED) scale as the primary outcome. Secondary outcomes include hemodynamic stability, recovery profile, postoperative pain scores, need for rescue medications, and adverse events.

Why it matters

Potential benefit: If successful, the preferred sedation approach could reduce the incidence of emergence delirium and improve recovery comfort and safety for children having burn procedures.

How similar studies have gone: Prior pediatric anesthesia studies have shown dexmedetomidine can reduce emergence delirium compared with some traditional sedatives, but direct comparisons with a midazolam‑ketamine combination specifically in burn deep sedation are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age from 3 to 16 years
* Both sexes
* Patients classified as American Society of Anesthesiologists (ASA) Physical -Status I-II
* Patients scheduled for elective burn-related procedures (e.g., burn dressing changes or minor interventions)

Exclusion Criteria:

* Refusal or inability to provide written informed consent from parent or legal guardian
* Known allergy or hypersensitivity to any of the study medications (midazolam, ketamine, or dexmedetomidine)
* Presence of hepatic dysfunction
* Presence of renal dysfunction
* Presence of immunological or hematological disorders
* History of epilepsy, developmental delay (mental retardation), or neurological deficits
* Patients receiving or requiring high doses of inotropes and/or vasopressors intraoperatively or postoperatively
* Preoperative hemodynamic instability, defined as uncontrolled hypertension, hypotension, or bradycardia

Where it's running

  • Ain Shams University
    Cairo, Egypt
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.